Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

Objective To estimate the association between the use of sodium glucose co-transporter-2 (SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies.Design We conducted a systematic review and meta-analysis of randomised controlled trials (RCT). Six large databases were searche...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kris Aubrey-Bassler, John-Michael Gamble, Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2019-02-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/9/1/e022577.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
by: Mazhar Hussain, et al.
Published: (2021-01-01)

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
by: Xiaoyan Liang, et al.
Published: (2025-01-01)

Optimización SGLT2 para cardionefro protección
by: Yukiko Harumi Yamasaki Ramos, et al.
Published: (2025-01-01)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
by: Wenjun Sha, et al.
Published: (2020-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Advances in sodium-glucose transporter protein 2 inhibitors and tumors
by: Jiaqi Wang, et al.
Published: (2025-02-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
by: Qasim Zafar Iqbal, et al.
Published: (2020-01-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
by: Caroline Wojtas, et al.
Published: (2023-01-01)

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors
by: Betül SÜMBÜL ŞEKERCİ, et al.
Published: (2025-01-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
by: Takuya Oyakawa, et al.
Published: (2025-01-01)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
by: Vasiliki Tsampasian, et al.
Published: (2021-01-01)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
by: Ranin Saad, et al.
Published: (2022-01-01)

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
by: Anastasia D. Egorova, et al.
Published: (2022-06-01)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2018-01-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care
by: Agnieszka Parfianowicz, et al.
Published: (2025-02-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin
by: Yu-Hsiang Lin, et al.
Published: (2025-02-01)

Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
by: Eun Hyung Cho, et al.
Published: (2018-01-01)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
by: Jun Muneuchi, et al.
Published: (2022-01-01)

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care
by: Dong-Dong Wang, et al.
Published: (2022-01-01)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice
by: Weiling Leng, et al.
Published: (2016-01-01)

Prevalence and risk factors of the most common multimorbidity among Canadian adults.
by: Obed Mortey, et al.
Published: (2025-01-01)

Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
by: Kyoung Hwa Ha, et al.
Published: (2025-02-01)

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells
by: Aiko Seki, et al.
Published: (2025-01-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
by: Hongsheng Li, et al.
Published: (2025-03-01)

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
by: Luis D'Marco, et al.
Published: (2021-01-01)

SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
by: Pasquale Paolisso, et al.
Published: (2024-11-01)

Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study
by: Robert W Platt, et al.
Published: (2025-01-01)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
by: Apichaya Chanawong, et al.
Published: (2023-01-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)